Annual Drug Patent Expirations for SOOLANTRA
Soolantra is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from three suppliers. There are twelve patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for SOOLANTRA.
This drug has seventy-three patent family members in twenty-eight countries.
The generic ingredient in SOOLANTRA is ivermectin. Three suppliers are listed for this compound. Additional details are available on the ivermectin profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
